Resources

We develop and share high-quality resources in collaboration with trusted partners, including Universities NGO’s and other global health partners.These materials are designed to support best practice, strengthen professional learning, and provide practical guidance informed by research and real-world experience. Explore toolkits, reports, and frameworks created to support impact across our network.

All resources on this website are free to download and use. We encourage individuals and organisations to share and adapt these materials for non-commercial purposes to support learning, training, and programme implementation.

Please acknowledge The Leprosy Mission Great Britain as the original source when using or adapting these resources. If you wish to use the materials for commercial purposes, please contact us to obtain permission.

 

Resources 

  1. OPL Grading toolkit: The OPL (Organisations of People affected by Leprosy) toolkit  is a practical assessment tool designed to evaluate the performance and governance of  local grassroots organisations. It provides a structured framework for assessing key areas such as leadership, member participation, meeting effectiveness, decision-making, and organizational management, helping identify both strengths and opportunities for improvement.

 

  1. Essential Care Package to address Mental Health and Stigma for persons with Neglected Tropical Diseases | InfoNTD  : Developed by the WHO and the NTD NGO Network, the Essential Care Package (ECP) is a framework integrating mental health support and stigma reduction into neglected tropical disease (NTD) programs.

 

  1. Safeguarding assessment toolkit : The Safeguarding Risk Assessment Guide is a practical tool that helps organisations identify, assess, and manage safeguarding risks across their programmes and activities. It provides a structured approach to evaluating potential risks, implementing appropriate mitigation measures, and strengthening safeguarding practices to protect children and adults at risk

 

  1. TLMGB response to International Development Committee (IDC) Civil society inquiry (2024)

 

  1. TLMGB Gender and Equity Policy  :The Leprosy Mission Great Britain (TLMGB) is committed to promoting gender equity and inclusion across all aspects of its work. As a Christian international development NGO, we recognise that gender inequality is both a cause and consequence of poverty, injustice and global health inequalities, and addressing it is essential to achieving our mission of transforming lives and ending leprosy.

 

 

Past publications

  • Jindal R, Singh I, Goyal D, Mittal A, Saini A, Dhoundiyal R, et al. Resistance to anti-leprosy drugs in multi-bacillary leprosy patients: The need for transformative action. Indian J Dermatol Venereol Leprol. 2026;92:37-42.

 

  • Darlong J, Nessa S, Singh I, et al. Protocol of a comparative multicentric non-inferiority clinical trial of WHO MBMDT with a new monthly chemotherapy regimen containing rifampicin, moxifloxacin and clarithromycin (RMC) in multibacillary patients from India. Trials. 2026. Published online Feb 17. doi:10.1186/s13063-026-09544-3

 

  • Darlong J, Kim J, Goswami S, et al. Understanding healing: A comparative analysis in chronic diseases with leprosy—a scoping review. PLoS Negl Trop Dis. 2026;20(3):e0013748. doi:10.1371/journal.pntd.0013748.

 

  • Darlong J, Govindasamy K, Gill P. Addressing multimorbidity in leprosy: A retrospective chart review from India. PLoS Negl Trop Dis. 2026;20(2):e0013503. doi:10.1371/journal.pntd.0013503.

 

  • Darlong J, Charles MV, Ilozumba O, et al. Sustaining community self-help groups beyond donor support: Lessons from a qualitative study of self-help groups, including persons affected by leprosy and disability in rural India. BMJ Open. 2026;16(1):e110417. doi:10.1136/bmjopen-2025-110417.

 

  • Guglani A, Lalmuanpuii G, Sharma R, Singh I, Dev T. Recurrent type 2 leprosy reaction: Keeping the threshold low to suspect drug-resistant Mycobacterium leprae. Int J Dermatol. 2025;64(8):1493-1494.

 

  • Putri AI, Peters RMH, De Sabbata K, et al. A socio-ecological model of the management of leprosy reactions in Indonesia and India using the experiences of affected individuals, family members and healthcare providers. BMC Health Serv Res. 2025;25:196. doi:10.1186/s12913-025-12340-5.

 

  • Singh V, Turankar RP, Pathak VK, et al. Investigating the role of soil-transmitted helminth infections in the development of leprosy in endemic regions. Front Immunol. 2025;16:1499304. doi:10.3389/fimmu.2025.1499304.

 

  • Sharma R, Singh I, Gupta S. Geographical trends of drug-resistant strains of Mycobacterium leprae in TLM hospitals: Insights from a four-year study across eleven hospitals in eight Indian states. Eur J Clin Microbiol Infect Dis. 2025.

 

  • Roy U, Panwar A, Cartwright MS, et al. High-resolution nerve ultrasound in the diagnosis of pure neuritic leprosy. J Clin Ultrasound. 2025;53(9):1966-1978.

 

  • Rawat D, Verma P, Dandu H, Malhotra K, Singh I, Suvirya S. Therapeutic paradox: Mycobacterium indicus pranii (MIP) vaccine-induced erythema nodosum necroticans and acute foot drop. Indian J Dermatol Venereol Leprol. Published online Sep 15, 2025.

 

  • Pathak VK, Singh I, Singh SV, Sengupta U. Understanding autoimmune response mechanisms in leprosy. Indian Dermatol Online J. 2025;16(5):709-716.

 

  • Palmeirim MS, Geluk A, de Jong BC, et al. Advancing Mycobacterium leprae transmission research: Insights from the R2STOP fund. PLoS Negl Trop Dis. 2025;19(8):e0013370.

 

  • Mathanraj I, Das P, Darlong J, Govindasamy K. Tibial drilling procedure to cover a large area of exposed tibia due to ulcerating ENL. Lepr Rev. 2025;96(2):e2025032. doi:10.47276/lr.96.2.2025032.

 

  • Roy S, Elkana M, Elkana V, Darlong J, Govindasamy K. Impact of tendon transfer surgery on function and participation levels among people affected by leprosy. Indian J Lepr. 2024;96:121-131.

 

  • Mathachan SR, Khurana A, Bansal A, Singhai M, Kumari R, Sardana K, et al. An atypical case of post-kala-azar dermal leishmaniasis with ulcers and verrucous lesions: Clinical and therapeutic implications. Am J Trop Med Hyg. 2024;110(1):40-43.

 

  • Pathak VK, Sharma A, Sharma A, et al. Diagnostic utility of multiplex polymerase chain reaction in patients with clinically suspected pure neuritic leprosy by identifying Mycobacterium leprae in skin biopsy samples and nasal swabs. Am J Trop Med Hyg. 2024;111(3):554-559. doi:10.4269/ajtmh.23-0777.

 

  • Dabas S, Khurana A, Singh I, et al. Th17 and T regulatory cytokines in serum, lesional skin, and stimulated peripheral blood mononuclear cell culture supernatants from type 1 leprosy reaction patients. Am J Trop Med Hyg. 2024;112(1):128-134. doi:10.4269/ajtmh.24-0358.

 

  • Singh S, Singh I, Herlekar R, et al. Unveiling the clinical and epidemiological significance of Mycobacterium lepromatosis detection in a patient with severe lepra reaction from India. Australas J Dermatol. 2024;65(7):596-598. doi:10.1111/ajd.14352.

 

  • Pathak VK, Singh I, Sharma B, Turankar RP, Arora M, Singh SV, Sengupta U. Unveiling the role of NK cells, NKT-like cells, and γδ T cells in the pathogenesis of type 1 reactions in leprosy. Heliyon. 2024;10:e25254.

 

  • Chhabra N, Kumar TS, Singh I, Ganguly S. Morphological index as a sensitive marker of drug resistance in leprosy: A case series. Indian J Dermatol. 2024;69(2):113-118.

 

  • Muddebihal A, Sardana K. Time to revisit the purported link of leprosy reactions with infective triggers: An unnecessary economic burden for patients. Trop Doct. 2024.

 

  • Napit IB, Shrestha D, Bishop J, Choudhury S, Dulal S, Gill P, Gkini E, Gwyther H, Hagge DA, Neupane K, Sartori J, Slinn G, Watson SI, Lilford R. An individual randomised efficacy trial of autologous blood products, leukocyte and platelet-rich fibrin (L-PRF), to promote ulcer healing in leprosy in Nepal: the TABLE trial protocol. Trials. 2021 Jul 15;22(1):453. PMID: 34266456; PMCID: PMC8281567.doi10.1186/s13063-021-05392-5

 

  • Napit IB, Shrestha D, Choudhury S, Gkini E, Ilozumba O, Gill P, Bishop J, Neupane K, Adhikari A, Sartori J, Watson SI, Lilford R. A randomised Trial of Autologous Blood products, leukocyte and platelet-rich fibrin (L-PRF), to promote ulcer healing in LEprosy: The TABLE trial. PLoS Negl Trop Dis. 2024 May 2;18(5):e0012088. PMID: 38696527; PMCID: PMC11093377. https://doi.org/10.1371/journal.pntd.0012088

 

  • Napit IB, Shrestha D, Neupane K, Adhikari A, Dhital R, Koirala R, Gopali L, Ilozumba O, Gill P, Watson SI, Choudhury S, Lilford RJ. Autologous blood products: Leucocyte and Platelets Rich Fibrin (L-PRF) and Platelets Rich Plasma (PRP) gel to promote cutaneous ulcer healing – a systematic review. BMJ Open. 2023 Dec 12;13(12):e073209. PMID: 38086583; PMCID: PMC10729115. https://doi.org/10.1136/bmjopen-2023-073209

 

  • Singh I, Pathak VK, Lavania M, Ahuja M, Sharma R, Narang T, et al. Genomic characterization of Mycobacterium lepromatosis from ENL patients from India. Infect Genet Evol. 2023.

 

  • Chhabra S, Narang T, Sahu S, Sharma K, Shilpa S, Sharma A, et al. High frequency of ofloxacin resistance patterns of Mycobacterium leprae from India: An indication to revisit second-line anti-leprosy treatment regimen. J Glob Antimicrob Resist. 2023.

 

  • Mathachan SR, Khurana A, Bansal A, Singhai M, Kumari R, Sardana K, et al. Case report: An atypical case of post-kala-azar dermal leishmaniasis with ulcers and verrucous lesions: Clinical and therapeutic implications. Am J Trop Med Hyg. 2023;110(1):40-43.

 

  • Patial M, Hanumanthu V, Chhabra S, Singh I, Chatterjee D, Narang T, Dogra S. Assessment of clinical, histopathological, and bacteriological findings in treated leprosy patients with persistent skin lesions: A retrospective cohort study. Am J Trop Med Hyg. 2023;109(6):1260-1265.

 

  • Patel NH, Padhiyar JK, Patel KA, Patel JR, Lakum MP, Singh I. Effective amelioration of the Lucio phenomenon with adjuvant tofacitinib therapy in a patient with dual infection of Mycobacterium leprae and Mycobacterium lepromatosis: A case report from India. Access Microbiol. 2023;5:000460.v3.

 

  • Pawar HS, Singh I, Sagar HK. Type 2 reaction-associated sensorineural hearing loss in a drug-resistant lepromatous leprosy patient: A case report. Asian Pac J Trop Med. 2023.

 

  • Turankar RP, Singh I, Lavania M. Modern molecular era of the mycobacterial world: Insights into diagnosis and transmission of mycobacteria and associated diseases. Front Trop Dis. 2023;4:22.

 

  • Singh I, Ahuja M, Lavania M, Pathak VK, Turankar RP, Singh V, et al. Efficacy of fixed-duration multidrug therapy for the treatment of multibacillary leprosy: A prospective observational study from northern India. Indian J Dermatol Venereol Leprol. 2023;89(2):226-232.

 

  • Bathula S, Khurana A, Singh I. Diagnosis of leprosy: Current updates and future directions. Indian J Postgrad Dermatol. 2023.

 

  • Muddebihal A, Sardana K, Khurana A, Sachdeva S, Singh I, Ahuja M, et al. A prospective case-control study of resistance to rifampicin, dapsone and ofloxacin in type 1 and type 2 leprosy reactions and the therapeutic impact of modified treatment regimen on reactions. J Eur Acad Dermatol Venereol. 2023;37(2):209.

 

  • Singh I, Goel A, Kumar A, Gupta S, Manjhi R, Mandal S, et al. National guidelines for surveillance of antimicrobial resistance in leprosy. New Delhi: Directorate General of Health Services; 2023.

 

  • Govindasamy K, Darlong J, Watson SI, Gill P. Prevalence of plantar ulcer and its risk factors in leprosy: A systematic review and meta-analysis. J Foot Ankle Res. 2023;16:77.

 

  • Ochalek J, Gibbs NK, Faria R, Darlong J, Govindasamy K, Harden M, et al. Economic evaluation of self-help group interventions for health in low- and middle-income countries: A scoping review. Health Policy Plan. 2023;38(9):1033-1049.

 

  • Darlong J, Govindasamy K, Ilozumba O, Choudhury S, Shrivastava A, Griffiths F, et al. An evaluation protocol of the Replicability Model project for detection and treatment of leprosy and related disability in Chhattisgarh, India. PLoS One. 2023;18(10):e0275763.

 

  • Butlin CR, Darlong J, Mukhier M. Access to thalidomide. Lepr Rev. 2023;94(3):186-192.

 

  • Choudhury S, Ilozumba O, Darlong J, Govindasamy K, Tsaku PA, Udo S, et al. Investigating the sustainability of self-help programmes in the context of leprosy and the work of leprosy missions in Nigeria, Nepal and India: A qualitative study protocol. BMJ Open. 2023;13:e070604.

 

  • Lockwood DNJ, Darlong J. Leprosy workers in the 21st century need to focus on better knowledge, early diagnosis and improved care: The theme of the International Leprosy Congress in Hyderabad, 2022. Lepr Rev. 2023;94(1):2-6.

 

  • Pai VV, Narasimha Rao P, Agarwal AK, Darlong J, Kar HK, Narang T, et al. Current practice and challenges with the use of multidrug therapy in the management of pediatric leprosy patients: An expert perspective from India. Indian J Lepr. 2023;95:293-297.

 

  • Pathak VK, Singh I, Singh SV, Sengupta U. Corroboration of cross-reactivity between Mycobacterium leprae and hosts’ salivary and cutaneous proteins: A hope for prognostic biomarkers for the pathogenesis of reactions in leprosy. Front Microbiol. 2022;13.

 

  • Ahuja M, Singh I, Lavania M, Pathak VK, Darlong J, Turankar RP, Hembrom S, Singh SV, Sengupta U. Ofloxacin resistance in multibacillary new leprosy cases from Purulia, West Bengal: A threat to effective second-line treatment for rifampicin-resistant leprosy. J Glob Antimicrob Resist. 2022;30:282-285.

 

  • Turankar RP, Singh V, Lavania M, Singh I, Sengupta U, Jadhav RS. Existence of viable Mycobacterium leprae in the natural environment and its genetic profiling in a leprosy-endemic region. Front Trop Dis. 2022;3:972682.

 

  • Jindal R, Singh I, Bhardwaj S, Chauhan P. High prevalence of resistance to anti-leprosy drugs in leprosy cases with chronic erythema nodosum leprosum: A matter of concern. Indian Dermatol Online J. 2022;13(4):511-513.

 

  • Narang T, Kamat D, Thakur V, Lavania M, Singh I, Ahuja M, Dogra S. Equal rates of drug resistance in leprosy cases with relapse and recurrent/chronic type 2 reaction: Time to revise the guidelines for drug-resistance testing in leprosy. Clin Exp Dermatol. 2022;47(2):297-302.

 

  • Roberts H, Mahato J, Govindasamy K, Darlong J, Raju MS. A study on depression using PHQ-9 among patients attending the outpatient department of a tertiary care leprosy hospital in Kolkata, West Bengal. Indian J Lepr. 2022;94:227-235.

 

  • Putri AI, de Sabbata K, Agusni RI, Alinda MD, Darlong J, de Barros B, Walker SL, Zweekhorst M, Peters RMH. Understanding leprosy reactions and the impact on the lives of people affected: An exploration in two leprosy-endemic countries. PLoS Negl Trop Dis. 2022;16(6):e0010476.

 

  • Govindharaj P, Srinivasan S, Darlong J. Disease disruption among people affected by leprosy. Indian J Lepr. 2022;94:23-31.

 

  • Darlong J, Govindasamy K, Daniel A. Characteristics of children with leprosy: Factors associated with delay in disease diagnosis. Indian J Dermatol Venereol Leprol. 2022;88:337-341.

 

  • Govindharaj P, Srinivasan S, Darlong J. The attitude of people affected by leprosy towards fellow people affected by leprosy in an endemic district of West Bengal, India. Indian J Lepr. 2022;94(4):287-297.